2026 年上半年中药股二级市场走势情况分析及下半年展望

●2026年上半年中药股指数下跌18.4%，同期上证指数上涨3.16%，生物医药指数仅下跌7.62%，中药板块显著跑输大盘及行业基准。72只成分股中仅8家上涨，64家下跌，个股分化剧烈。●下跌源于多重因素：①资金面：市场主线集中于AI、半导体等科技赛道，资金大幅流出中药板块；机构持续减配，北向资金与医药基金净流出，形成“下跌—无人问津”负反馈。②政策面：中成药集采扩围压缩毛利率；2026年新版监管规则要求完善临床数据，抬高经营成本；医保与药店飞行检查常态化，终端动销承压。③基本面：天然牛黄、麝香等名贵药材成本刚性上涨，终端需求恢复不及预期，渠道去库存，片仔癀、同仁堂等业绩阶段性下滑，打破长期稳定增长预期。●展望未来，我们认为，中药板块当前处于政策底、估值底、业绩底三重拐点：①估值极低：中证中药指数PE约21倍，处近十年3%-5%分位，安全边际充足；公募持仓仅0.26%，为近五年低位。②业绩触底回升：2025年四季度营收转正，2026年一季度净利润增速转正，上游成本压力缓解，复苏趋势确立。③政策红利释放：7月强制再注册新规落地，将加速淘汰不合规批文（超七成说明书不全市场份额向龙头集中；“人用经验+临床”简化审评、医保扩容、基层中医药配套等持续利好头部企业。三大主线值得关注：第一，全国性综合龙头（稳健底仓第二，拥有独家配方、心脑血管等特色品种的细分龙头（弹性大第三，创新转型企业（经典名方、配方颗粒等成长赛道）。一、2026年上半年中药股表现不佳、下跌0.79%2026年上半年中药股指数跌了18.4%，生物医药指数则下跌了7.2%。中药股指数跑输生物医 8只上涨股票分别是：康惠股份上涨105.72%、粤万年青上涨36.24%、众生药业上涨30.60%、证券代码证券简称前收盘价2026-01-02收盘价[不复权],[元]2026-06-30收盘价[不复权],[元]区间涨跌，[单位]元[起始交易日期]2026-1-5[截止交易日期]2026-6-30区间涨跌幅（%）[起始交易日期]2025-1-2[截止交易日期]2025-6-30603139.SH康惠股份20.470042.110021.6400105.7157301111.SZ粤万年青19.030025.88006.896836.2417002317.SZ众生药业18.980024.57005.807430.5976300878.SZ维康药业25.510032.33006.820026.7346600381.SH*ST春天4.43005.10000.670015.1242600222.SH太龙药业6.58007.26000.690710.4973603439.SH三力制药11.700012.61000.96928.2834300147.SZ*ST香雪9.10009.51000.41004.5055002424.SZST百灵4.35004.3400-0.0100-0.2299600538.SH国发股份6.12006.0600-0.0600-0.9804600750.SH华润江中23.170022.0700-0.2711-1.1700600285.SH羚锐制药20.710019.3800-0.3100-1.4969600671.SH天目药业17.310016.8800-0.4300-2.4841600479.SH千金药业10.16009.3000-0.4804-4.7284000423.SZ东阿阿胶49.080045.3600-2.3712-4.8313688799.SH华纳药厂47.700044.8700-2.8300-5.9329600351.SH亚宝药业6.49005.7500-0.4224-6.5080603858.SH步长制药15.640014.6000-1.0400-6.6496002107.SZ沃华医药6.24005.6900-0.4228-6.7757000989.SZ九芝堂8.73007.7700-0.7038-8.0624600572.SH康恩贝4.46003.9200-0.3945-8.8443000623.SZ吉林敖东19.530017.7300-1.8000-9.2166002603.SZ以岭药业17.070015.0000-1.5839-9.2791600566.SH济川药业26.300022.1900-2.5437-9.6717000790.SZ华神科技3.87003.4900-0.3800-9.8191000650.SZ仁和药业5.65005.0900-0.5600-9.9115002412.SZ汉森制药6.41005.5000-0.6477-10.1042600211.SH西藏药业42.550037.3900-4.3514-10.2266300181.SZ佐力药业16.160014.1000-1.7042-10.5458002275.SZ桂林三金14.100012.1900-1.6302-11.5617600535.SH天士力15.070013.2300-1.7436-11.5698002349.SZ精华制药7.26006.2100-0.9695-13.3535600329.SH达仁堂45.620037.2200-6.3467-13.9120000538.SZ云南白药56.760047.3700-7.9792-14.0577920566.BJ梓橦宫11.12009.2300-1.6865-15.1661002864.SZ盘龙药业30.840025.8000-5.0400-16.3424600557.SH康缘药业14.110011.7700-2.3400-16.5840002390.SZ信邦制药3.22002.6100-0.5595-17.3753603998.SH方盛制药11.24009.0300-1.9543-17.3871002826.SZ易明医药18.380015.0300-3.2036-17.4298300026.SZ红日药业3.52002.9000-0.6200-17.6136002287.SZ奇正藏药23.660018.8400-4.4332-18.7371300519.SZ新光药业14.900011.8500-2.7950-18.7583000999.SZ华润三九28.460022.4900-5.4082-19.0029002566.SZ益盛药业7.63006.0400-1.5212-19.9367600332.SH白云山25.740020.0400-5.2768-20.5005300158.SZ振东制药5.81004.6100-1.2000-20.6540002644.SZ佛慈制药8.64006.8100-1.8111-20.9613600993.SH马应龙28.000021.6200-6.3800-22.7857600976.SH健民集团33.570024.9100-7.9653-23.7274002737.SZ葵花药业14.770011.2100-3.5600-24.1029600129.SH太极集团18.050013.5700-4.4800-24.8199300534.SZ陇神戎发9.48007.0800-2.3832-25.1391600594.SH益佰制药3.98002.9700-1.0100-25.3769600613.SH神奇制药6.07004.4400-1.5657-25.7933002873.SZ新天药业9.92007.3200-2.5754-25.9618000590.SZ古汉医药11.21008.1700-3.0400-27.1186920433.BJ大唐药业5.87004.2500-1.6200-27.5980600771.SH广誉远17.980012.9500-5.0300-27.9755300039.SZ上海凯宝6.03004.2600-1.6892-28.0127600085.SH同仁堂32.260023.1100-9.1500-28.3633002773.SZ康弘药业29.970020.4500-8.8017-29.3685000766.SZ通化金马27.490019.4000-8.0900-29.4289920266.BJ生物谷9.07006.2100-2.8600-31.5325603896.SH寿仙谷19.380012.9500-6.4300-33.1785600436.SH片仔癀168.7800109.2800-59.5000-35.2530600252.SH中恒集团2.74001.7600-0.9800-35.7664600518.SH康美药业1.91001.2000-0.7100-37.1728600422.SH昆药集团12.56007.8100-4.7500-37.8185300049.SZ福瑞医科70.410038.8800-31.5300-44.7806603567.SH珍宝岛8.93004.3800-4.5500-50.9518002198.SZST嘉应7.03003.0300-4.0000-56.8990二、对上半年中药板块二级市场表现不佳原因的分析 赎回带来被动卖出，板块长期处于净流出状态；市场形